Emanuele Zucca
International Extranodal Lymphoma Study Group (IELSG) - Bellinzona (Switzerland) · Oncology Institute of Southern Switzerland - Bellinzona, CH · Oncology Institute of Southern Switzerland
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emanuele Zucca as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:02 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05735834 · Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsInternational Extranodal Lymphoma Study Group (IELSG) · active not recruiting · Splenic Marginal Zone Lymphoma · study chair
- Ph2NCT04646395 · Study of Acalabrutinib and Tafasitamab in MZL PatientsInternational Extranodal Lymphoma Study Group (IELSG) · active not recruiting · Marginal Zone Lymphoma · study chair
- N/ANCT04333524 · FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic RoleInternational Extranodal Lymphoma Study Group (IELSG) · active not recruiting · Marginal Zone Lymphoma · study chair
- Ph1NCT03886649 · Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.Swiss Cancer Institute · terminated · Non-Hodgkin Lymphoma · study chair
- Ph2NCT03031483 · Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · completed · Mucosa Associated Lymphoid Tissue (MALT) Lymphoma · study director
- Ph2NCT02451111 · Rituximab With or Without Ibrutinib for Patients With Advanced Follicular LymphomaSwiss Cancer Institute · terminated · Follicular Lymphoma · study chair
- Ph2NCT01808599 · Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · active not recruiting · MALT Lymphoma · principal investigator
- Ph2NCT01307605 · Rituximab With or Without Lenalidomide in Treating Patients With Previously Untreated Follicular LymphomaSwiss Cancer Institute · terminated · Lymphoma · study chair
- Ph2NCT01164267 · Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)International Extranodal Lymphoma Study Group (IELSG) · completed · Marginal Zone B-cell Lymphoma · study chair
- N/ANCT01142674 · T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell LymphomaAssociazione Angela Serra per la ricerca sul cancro · completed · Lymphoma, T-Cell, Peripheral · study chair
- Ph2NCT01011920 · Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · completed · Central Nervous System Lymphoma · principal investigator
- Ph2NCT00945724 · Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of TestisInternational Extranodal Lymphoma Study Group (IELSG) · completed · Large B-cell Diffuse Lymphoma of Testis · study chair
- Ph2NCT00210379 · Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · completed · Lymphoma, B Cell · study chair
- Ph2NCT00210314 · Phase II Trial of Combined Modality Treatment in Primary Central Nervous System LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · completed · Lymphoma, B Cell · study chair
- Ph3NCT00210353 · Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT LymphomaInternational Extranodal Lymphoma Study Group (IELSG) · completed · Lymphoma, Mucosa-Associated Lymphoid Tissue · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:02 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- 507 citationsRCR 19.1
- 500 citationsRCR 13.9
- 457 citationsRCR 9.7
- Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.Lancet Haematol · 2016381 citationsRCR 10.4
- 318 citationsRCR 11.8
- Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.Blood · 2003311 citationsRCR 7.5
- Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.J Clin Oncol · 2010200 citationsRCR 4.5
- 183 citationsRCR 5.1
- Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.J Clin Oncol · 2005181 citationsRCR 4.4
- 171 citationsRCR 5.2